Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

NCT01930006 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Mirati Therapeutics Inc.